Mallinckrodt plc (MNK)
MNK moved a median of +0.04% 30 minutes after news, and -0.14% by the close. How MNK actually reacts to news — the realized, point-in-time move the market made, measured across 1,581 labeled events over its full measured history with zero look-ahead.
MNK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.07% | 53% | 1,426 |
| 30-min | +0.04% | 53% | 1,447 |
| 60-min | +0.02% | 51% | 1,460 |
| to close | -0.14% | 46% | 1,474 |
| Middle 50% of MNK reactions | -0.84% to +1.23% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 1,581 |
Half of all Mallinckrodt plc news events land between -0.84% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MNK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MNK's baseline. Nothing else.
Recent MNK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting | Press release | PR Newswire | — | — | |
| Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting | Press release | PR Newswire | — | — | |
| Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives | Press release | PR Newswire | — | — | |
| Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe | Press release | PR Newswire | — | — | |
| Keenova Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | — | — | |
| Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology | Press release | PR Newswire | — | — | |
| Keenova Therapeutics to Report Second Quarter 2026 Financial Results on August 11, 2026 | Press release | PR Newswire | — | — | |
| Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research | Press release | PR Newswire | — | — | |
| Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis | Press release | PR Newswire | — | — | |
| Keenova Champions Men's Health Month with Education and Outreach | Press release | PR Newswire | — | — | |
| Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting | Press release | PR Newswire | — | — | |
| Keenova Reports First Quarter 2026 Financial Results | Press release | PR Newswire | — | — | |
| Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | Press release | PR Newswire | — | — | |
| Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | Press release | PR Newswire | — | — | |
| Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026 | Press release | PR Newswire | — | — | |
| Keenova Announces Unaudited Fourth Quarter 2025 Financial Results | Press release | PR Newswire | — | — | |
| Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge | Press release | PR Newswire | — | — | |
| Keenova Publishes XIAFLEX® (collagenase clostridium histolyticum) Analysis in Journal of Hand Surgery Global Online | Press release | PR Newswire | — | — | |
| Keenova Unveils Clinical Data from Phase 2 Plantar Fibromatosis Study at the ACFAS Annual Meeting | Press release | PR Newswire | — | — | |
| Keenova Announces New Manuscript on Plantar Fibromatosis Treatment Patterns in Peer-Reviewed Journal of Foot and Ankle Surgery | Press release | PR Newswire | — | — | |
| Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition | Press release | PR Newswire | — | — | |
| Keenova Announces New Dupuytren's Contracture Survey Presentation About Patient Perceptions and Treatment Outcomes | Press release | PR Newswire | — | — | |
| Keenova to Participate in the Jefferies Global Healthcare Conference in London | Press release | PR Newswire | — | — | |
| Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics | Press release | PR Newswire | — | — | |
| Mallinckrodt Reports Third Quarter 2025 Financial Results | Press release | PR Newswire | — | — | |
| Mallinckrodt to Present Data on Terlipressin at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting | Press release | PR Newswire | — | — | |
| Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025 | Press release | PR Newswire | — | — | |
| Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day | Press release | PR Newswire | — | — | |
| Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection) | Press release | PR Newswire | — | — | |
| Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer | Press release | PR Newswire | — | — | |
| Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance | Press release | PR Newswire | — | — | |
| Mallinckrodt Names Leslie Donato to Board of Directors | Press release | PR Newswire | — | — | |
| Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader | Press release | PR Newswire | — | — | |
| Mallinckrodt plc to Report Earnings Results for Second Quarter 2025 | Press release | PR Newswire | — | — | |
| Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector | Press release | PR Newswire | — | — | |
| Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company | Press release | PR Newswire | — | — | |
| Mallinckrodt Presents Data on Real-World Outcomes with Acthar® Gel (repository corticotropin injection) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025) | Press release | PR Newswire | — | — | |
| Mallinckrodt and Endo Announce Significant Progress in Proposed Merger | Press release | PR Newswire | — | — | |
| Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance | Press release | PR Newswire | — | — | |
| Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2025 Digestive Disease Week (DDW) Annual Meeting | Press release | PR Newswire | — | — | |
| Mallinckrodt plc to Report Earnings Results for First Quarter 2025 | Press release | PR Newswire | — | — | |
| Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader | Press release | PR Newswire | — | — | |
| Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance | Press release | PR Newswire | — | — | |
| Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025 | Press release | PR Newswire | — | — | |
| Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results | Press release | PR Newswire | — | — | |
| Mallinckrodt Completes Divestiture of Therakos® Business | Press release | PR Newswire | — | — | |
| Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting | Press release | PR Newswire | — | — | |
| Mallinckrodt to Present at Jefferies London Healthcare Conference | Press release | PR Newswire | — | — | |
| Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance | Press release | PR Newswire | — | — | |
| Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting | Press release | PR Newswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MNK section they belong to.
Where else MNK is measured.
MNK earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ADMA Biologics Inc (ADMA) | 1,609 | +0.11% | 52% |
| VARIAN MEDICAL SYSTEMS (VAR) | 1,602 | +0.02% | 51% |
| AmerisourceBergen Corporation (ABC) | 1,573 | +0.02% | 51% |
| CTI BioPharma Corp. (CTIC) | 1,481 | -0.33% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Mallinckrodt plc's median reaction calculated?
Every labeled MNK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,581 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of MNK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MNK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.